Dosage, effectiveness, and safety of sertraline treatment for posttraumatic stress disorder in a Japanese clinical setting: a retrospective study

Abstract

BackgroundMany of the posttraumatic stress disorder (PTSD) treatment guidelines recognize the use of selective serotonin reuptake inhibitors as first-line pharmacological treatment. In Japan, there were no published studies investigating the effectiveness and safety of sertraline for PTSD in a clinical setting.MethodsWe conducted a retrospective medical chart review of the dosage, effectiveness, and safety of sertraline for the PTSD treatment in Japan. Data were collected from medical charts of patients of PTSD, caused by various types of trauma, who were treated with sertraline between July 2006 and October 2012 during their regular clinical practice. To evaluate the effectiveness, the investigators retrospectively assessed the severity and improvement of the symptoms using the Clinical Global Impressions − Severity and the Clinical Global Impressions − Improvement.ResultsThe study population was 122 Japanese patients aged ≥18 years with a diagnosis of PTSD who were treated with sertraline (median duration, 10.6 months). Doses ranged from 12.5 to 150 mg/day, mostly 25 and 50 mg/day. The median duration of observation was 10.8 months. Out of those, 50% of patients were regarded as responders by using the Clinical Global Impressions - Improvement at the end of sertraline treatment or the last observation. Two-thirds (65.6%) of patients improved in the severity of PTSD, as assessed by Clinical Global Impressions - Severity, whereas 32.8% showed no change, and 1.6% worsened. Subgroups analyses and logistic regression analyses suggested that the type of traumatic events was the factor with the highest influence on the response rate. The adverse events in this chart review were consistent with the known safety profile of sertraline. There were no reports of serious or severe adverse events considered to be related to sertraline.ConclusionsOur study suggested the effectiveness of sertraline for the treatment of PTSD in a Japanese clinical setting, and the obtained safety profile was consistent with the generally known safety profile of sertraline.Trial registrationClinicalTrials.gov (Identification No. NCT01607593). Registered May 21, 2012.

Selective dopamine D3 receptor antagonism significantly attenuates stress‐induced immobility in a rat model of post‐traumatic stress disorder

“…With respect to the predictive validity of the SPS model, it has been reported that the anxiety-like behaviors shown by rats after undergoing SPS exposure are attenuated by chronic administration of the selective serotonin reuptake inhibitors (SSRIs) fluoxetine (Shafia et al, 2017) or paroxetine (Takahashi et al, 2006; Wang et al, 2008). This finding is consistent with clinical data suggesting that SSRIs have efficacy in the chronic treatment of PTSD (Kamo et al, 2016; Roberts, 2006; van der Kolk et al, 2007; Xu et al, 2011), although complete remission of symptoms occurs in only 20-30% of PTSD patients (Berger et al, 2009). Finally, it should be noted that the SPS model meets the criteria listed for PTSD in the Diagnostic and Statistical Manual on Mental Disorders V (Borghans and Homberg, 2015).…”

Transcutaneous electrical acupoint stimulation for post‐traumatic stress disorder: Assessor‐blinded, randomized controlled study

“…Patients in groups A and D received open‐label sertraline treatment. The reason for the choice of sertraline is that this SSRI has been widely used in the treatment of PTSD; its dosage, effectiveness, and safety has been well established in Asian patients with PTSD . Sertraline was commenced at 25 mg/day and increased by 25 mg/day every other day to achieve the optical dosage in ≤7 days, but the maximum dose would not exceed 100 mg/day.…”

Effects of Antidepressants on Sleep in Post-traumatic Stress Disorder: An Overview of Reviews

“…In a retrospective medical chart review of the dosage, effectiveness, and safety of sertraline (12.5-150 mg daily, most common doses 25-50 mg daily, median duration of treatment = 10.6 months) on a Japanese cohort of patients with PTSD caused by various types of trauma [ 103 ], the authors reported somnolence to be among the most common adverse events (N = 11, 9%), and one of the most common causes of discontinuation of treatment (3 patients, 2.45%).…”